316 results on '"Pantuck, Allan J."'
Search Results
2. MP46-03 PIVOTAL TRIAL OF MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION IN MEN WITH LOCALIZED PROSTATE CANCER: THREE-YEAR FOLLOW-UP
3. Reply by Authors
4. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer
5. MP14-03 THE UCLA HISTO-GENETIC RISK CLASSIFICATION (U-HGRC) TO PREDICT OUTCOMES OF LOCALIZED CLEAR-CELL RENAL CELL CARCINOMA
6. MP36-19 THE ROLE OF OBESITY IN THE INCIDENCE OF LYMPHATIC SPREAD, DISEASE-FREE AND OVERALL SURVIVAL: DATA FROM THE ARISER CLINICAL TRIAL
7. MP61-17 INITIAL MULTICENTER EXPERIENCE UTILIZING AN ABSORBABLE RADIOPAQUE HYDROGEL FOR PATIENTS WITH INVASIVE BLADDER TUMORS
8. MP36-12 VALIDATION OF THE CAIX SCORE AS A PROGNOSTIC BIOMARKER FOR LYMPHATIC SPREAD AND CANCER-SPECIFIC SURVIVAL
9. MP77-08 MITOGEL: OPTIMIZING DRUG DELIVERY TO THE UPPER URINARY TRACT—A PRECLINICAL EVALUATION
10. MP35-06 EFFECTS OF DENDRITIC CELL-BASED AD-GM∙CAIX VACCINE AS MONOTHERAPY OR IN COMBINATION WITH SUNITINIB IN AN IMMUNOCOMPETENT MOUSE MODEL OF METASTATIC RENAL CELL CARCINOMA
11. Prognostic Impact of Preoperative Neutrophil-to-Lymphocyte Ratio in Localized Nonclear Cell Renal Cell Carcinoma
12. 2003 ANTITUMOR ACTIVITY OF SUNITINIB VERSUS OTHER FDA-APPROVED TARGETED CANCER AGENTS AGAINST METASTATIC RENAL CELL CARCINOMA IN THE FIRST-LINE SETTING
13. 2002 NON-CLEAR CELL HISTOLOGY IS INDEPENDENTLY ASSOCIATED WITH POOR OUTCOMES IN THE TARGETED THERAPY ERA
14. 304 DC-AD-GMCAIX BASED VACCINE THERAPY IS SAFE AND EFFECTIVE IN IMMUNOCOMPETENT MURINE KIDNEY CANCER TUMOR MODELS
15. 979 UISS RISK STRATIFICATION CAN IDENTIFY PATIENTS LESS LIKELY TO BENEFIT FROM CYTOREDUCTIVE NEPHRECTOMY IN THE TARGETED THERAPY ERA
16. Prognostic Value of Microvascular Invasion in Predicting the Cancer Specific Survival and Risk of Metastatic Disease in Renal Cell Carcinoma: A Multicenter Investigation
17. The Chromophobe Tumor Grading System is the Preferred Grading Scheme for Chromophobe Renal Cell Carcinoma
18. Integrated Safety Data From 4 Randomized, Double-Blind, Controlled Trials of Autologous Cellular Immunotherapy With Sipuleucel-T in Patients With Prostate Cancer
19. Use of Abiraterone for Prostate Cancer
20. Pathological, Immunohistochemical and Cytogenetic Features of Papillary Renal Cell Carcinoma With Clear Cell Features
21. Development and External Validation of a Nomogram Predicting Disease Specific Survival After Nephrectomy for Papillary Renal Cell Carcinoma
22. Absent CD44v6 Expression is an Independent Predictor of Poor Urothelial Bladder Cancer Outcome
23. 674 INTEGRATED SAFETY RESULTS FROM FOUR RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF SIPULEUCEL-T
24. 509 IS BASELINE RENAL FUNCTION A DECISION-MAKING CRITERION FOR CHOOSING AN ABLATIVE TECHNIQUE RATHER THAN A PARTIAL NEPHRECTOMY IN SMALL RENAL MASSES?
25. Editorial Comment
26. Conditional Survival Predictions After Nephrectomy for Renal Cell Carcinoma
27. Cytoreductive Nephrectomy for Kidney Cancer With Sarcomatoid Histology—Is Up-Front Resection Indicated and, if Not, is it Avoidable?
28. CA9 Gene: Single Nucleotide Polymorphism Predicts Metastatic Renal Cell Carcinoma Prognosis
29. CHROMOSOME 9P DELETIONS IN SMALL CLEAR CELL RENAL CARCINOMA TUMORS (<4 CM) ARE ASSOCIATED WITH SYNCHRONOUS AND METACHRONOUS METASTATIC DISEASE
30. THE USE OF NEPHRON SPARING SURGERY MAY FAVORABLY IMPACT THE RISK OF NON CANCER RELATED DEATH IN RENAL CELL CARCINOMA SURVIVORS
31. A NOMOGRAM PREDICTING DISEASE-SPECIFIC SURVIVAL AFTER NEPHRECTOMY FOR PAPILLARY RENAL CELL CARCINOMA
32. ABSENCE OF CD44 EXPRESSION IS AN INDEPENDENT PREDICTOR OF POOR OUTCOME FOR PATIENTS WITH UROTHELIAL BLADDER CANCER
33. CARBONIC ANHYDRASE IX AS A NOVEL TARGET FOR DETECTION AND THERAPY OF LOW GRADE UROTHELIAL CELL CARCINOMA
34. EARLY RENAL FUNCTION OUTCOMES FOLLOWING OPEN VS LAPAROSCOPIC PARTIAL NEPHRECTOMY: HOW DO THEY COMPARE?
35. EFFECT OF WARM ISCHEMIA TIME ON RENAL DIFFERENTIAL RENAL FUNCTION AFTER RENAL ARTERY CLAMPING FOR LAPAROSCOPIC PARTIAL NEPHRECTOMY
36. RENAL FUNCTION AND LOCAL RECURRENCE AFTER PARTIAL NEPHRECTOMY IN SOLITARY KIDNEYS
37. NEPHRON SPARING SURGERY (NSS) IS SUPERIOR TO RADICAL NEPHRECTOMY IN PRESERVING RENAL FUNCTION OUTCOME IN TUMORS LARGER THAN 4 CM
38. CHROMOSOME 9P DELETIONS IN CLEAR CELL RENAL CELL CARCINOMA ARE ASSOCIATED WITH AGGRESSIVE DISEASE
39. VHL INDUCES EPITHELIAL TO MESENCHYMAL TRANSITION (EMT) IN AN NF -κ B DEPENDENT MANNER
40. EXTENT OF TUMOR NECROSIS IS AN INDEPENDENT PROGNOSTIC FACTOR FOR PAPILLARY RENAL CELL CARCINOMA
41. LONG TERM FOLLOW UP OF PHASE 2 STUDY OF POMEGRANATE JUICE FOR MEN WITH PROSTATE CANCER SHOWS DURABLE PROLONGATION OF PSA DOUBLING TIME
42. THE INCIDENCE OF BENIGN RENAL MASS NEGATIVELY CORRELATES WITH TUMOR SIZE IN MEN ONLY AND IS INFLUENCED BY SURGICAL APPROACH - A MULTICENTRIC STUDY
43. ACTIVITY OF GMP GRADE ADENOVIRUS GM-CAIX: A NOVEL MOLECULAR TARGETED VACCINE THERAPY FOR KIDNEY CANCER
44. Presence of Tumor Necrosis is Not a Significant Predictor of Survival in Clear Cell Renal Cell Carcinoma: Higher Prognostic Accuracy of Extent Based Rather Than Presence/Absence Classification
45. Intraoperative Thrombus Embolization During Nephrectomy and Tumor Thrombectomy: Critical Analysis of the University of California-Los Angeles Experience
46. Editorial Comment
47. Tumor Size Does Not Predict Risk of Metastatic Disease or Prognosis of Small Renal Cell Carcinomas
48. MOLECULAR PROGNOSTIC TUMOR PROFILING OF TYPE 1 AND TYPE 2 PAPILLARY RENAL CELL CARCINOMA: RELEVANCE TO THE DEVELOPMENT OF TUMOR-SPECIFIC TARGETED THERAPIES
49. PARTIAL NEPHRECTOMY FOR RENAL MASSES: CAN WE APPLY THE QUALITY OF CARE CONCERN ADDRESSED BY THE UROLOGICAL COMMUNITY, TO THE EUROPEAN POPULATION?
50. NEPHRON-SPARING SURGERY VS. RADICAL NEPHRECTOMY IN PATIENTS WITH RENAL CELL CARCINOMA >7 CM. WITH NO EVIDENCE OF NODAL OR DISTANT METASTATSIS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.